New Jersey Innovation Institute, a New Jersey Institute of Technology corporation, announced Tuesday it has signed an industry participation agreement with Pall Corp. to support the development of its BioPharmaceutical Innovation Lab.
Pall, a high-tech filtration equipment provider, has agreed to invest $3.5 million to advance NJII’s Cell & Gene Therapy Center.
The partnership will support two centers at NJII that focus on manufacturing new cell and gene therapies: the Cell and Gene Therapy Development Center and the Center of Advanced Biologic Manufacturing.
“We are excited to work with Pall Corporation, a world leader in high-tech filtration, separation and purification, to advance manufacturing of new cell and gene therapies. These therapies represent a new era in the treatment of cancer and other major diseases and hold great promise in achieving successful patient outcomes,” Dr. Haro Hartounian, senior executive director, biotechnology and pharmaceutical innovation, NJII.
The Cell and Gene Therapy Development Center will focus on addressing manufacturing process technologies and workforce development challenges faced by the industry.
The Center of Advanced Biologic Manufacturing will focus on addressing challenges of mass production through continuous processing and viral vector manufacturing.
“Scaling up the manufacture of gene therapies and gene-modified cell therapies to industrial levels is one of the biggest challenges in modern medicine manufacture. If we’re going to tackle the industry’s productivity challenges, we need to think smart and invest in finding innovative manufacturing solutions, for example through continuous bioprocessing. NJII is doing remarkable work in this area and we’re very excited to partner with them on this innovative program,” Peter Levison, Pall’s executive director business development, said.
